替米沙坦对肥胖性高血压患者微量尿白蛋白及C反应蛋白的影响

The Effects of Telmisartan to The C-reactive Protein and Microalbuminuria Levels in Obesity Associated Hypertension People

目的探讨替米沙坦对肥胖性高血压患者微量尿白蛋白(MAU)及C反应蛋白(CRP)的影响。方法 100例诊断为轻中度高血压的肥胖患者,应用随机数字表法分为两组,对照组给予氨氯地平治疗;观察组给予替米沙坦治疗,两组患者各50例。患者入组后每2周随访1次,观察周期为24周,治疗前后监测血压变化、腰围及体质量指数(BMI),CRP水平变化及MAU的变化情况。结果治疗24周后:①观察组平均收缩压(130±8)mm Hg,对照组平均收缩压(135±9)mm Hg;观察组平均舒张压(82±6)mm Hg,对照组平均舒张压(85±6)mm Hg,比较差异均有统计学意义(P<0.05)。②观察组腰围(93.2±3.8)cm,对照组腰围(94.7±3.6)cm;观察组BMI(29.8±3.2)kg/m2,对照组(31.4±3.1)kg/m2,观察组治疗前后比较及两组治疗后比较差异均有统计学意义(P<0.05)。③观察组CRP降低至(17.52±6.48)ng/L,对照组降低至(20.47±7.08)ng/L;观察组MAU水平降至(20.86±13.87)mg/L,对照组降低至(26.82±14.63)mg/L,观察组治疗前后比较及两组治疗后比较差异有统计学意义(P<0.05)。结论替米沙坦治疗肥胖性高血压比氨氯地平可更有效地控制血压,降低肥胖相关指数,降低CRP和尿MAU水平,值得临床推广应用。

Objective To explore the effects of telmisartan to the C-reactive protein （CRP）and the microalbuminuria（MAU） of obesity associated hypertension patients. Methods One hundred mild and mod-erate hypertension and obesity people were divided into two groups by random-number table method, the amlodipine（control） group and the telmisartan（observation） group ,50 patients in each group. All the patients were visited every 2 weeks, altogether for 24 weeks. And before and after treatment, the blood pressure, waist circumference（ WC ）and body mass index （BMI）, CRP and MAU were measured. Results 24 weeks after treatment, ①SBP in the observation group was （ 130 ± 8 ） mmHg vs in the control group （ 135 ± 9 ） mm Hg, DBP in the observation group was（ 82 ± 6 ）vs control control（ 85 ± 6） mm Hg, the differences were statistical-ly significant（ P 〈 0. 05 ）. ②WC in the observation group was （93.2 ± 3.8 ） cm vs in the control group （94. 7 ± 3.6） cm;BMI in the observation group was （29.8 ± 3.2 ） kg/m^2 vs in the control group （31.4 ± 3.1 ） kg/m^2, Both the comparison of the observation group before and after treatment, and the comparison between two groups after treatment were statistically significant（ P 〈 0.05 ）. ③CRP in the observation group decreased to （17.52 ± 6.48） ng/L vs in the control group decreased to（20.47 ± 7.08 ） ng/L, MAU in the observation group decreased to （20.86 ± 13.87 ） mg/L vs in the control group decreased to （20.86 ± 13.87 ） mg/L, Both the comparison of the observation group before and after treatment, and comparison between the two groups after treatment were statistically significant （ P 〈 0.05 ）. Conclusion Telmisartan is more effective than amlodipine in controlling the blood pressure, lowering the obesity related indexes, and decreasing the CRP and MAU level in treating obesity associated hypertension, which is worth clinical application.